Company: MYGN
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0000899923-25-000086
Chunk: 83

Company: MYRIAD GENETICS INC
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 8
Chunk 83
---
 June 30, 2025 and 2024 are as follows:Six Months Ended June 30,(in millions)20252024Cash paid for income taxes$0.3 $1.3 Cash paid for interest1.7 0.7 Non-cash investing and financing activities: Change in operating lease right-of-use assets and lease liabilitiesOperating lease right-of-use assets$1.8 $(0.3)Operating lease liabilities(1.8)(3.1)Purchases of property, plant, and equipment and capitalization of intangible assets in accounts payable and accrued liabilities4.9 1.7 The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the Condensed Consolidated Balance Sheets that agrees to the amounts included in the Condensed Consolidated Statements of Cash Flows.June 30,(in millions)20252024Cash and cash equivalents$74.4 $92.4 Restricted cash9.3 8.8 Total cash, cash equivalents, and restricted cash$83.7 $101.2 

18

15. ACCUMULATED OTHER COMPREHENSIVE LOSS

The functional currency of the Company’s international subsidiaries is the local currency. For those subsidiaries, expenses denominated in the functional currency are translated into U.S. dollars using average exchange rates in effect during the period and assets and liabilities are translated using period-end exchange rates. The foreign currency translation adjustments are included in Accumulated other comprehensive loss as a separate component of Stockholders’ equity.The following table shows the cumulative translation adjustments included in Accumulated other comprehensive loss:(in millions)Ending balance December 31, 2024$(0.8)Period translation adjustments0.7 Ending balance June 30, 2025$(0.1)

16.SUBSEQUENT EVENTS

New Credit FacilityOn July 31, 2025 (the "Closing Date"), the Company entered into a Credit Agreement (the "Credit Agreement") with the lenders from time to time party thereto, and OrbiMed Royalty & Credit Opportunities IV, LP., as administrative agent (the "Administrative Agent") and as initial lender (“OrbiMed”). The Credit Agreement consists of a $200 million term loan credit facility with an initial term loan of $125 million (the "Initial Loan"), which amount was funded on the Closing Date, and delayed draw term loans (the "Delayed Draw Loans" and together with the Initial Loan, the "